Evidence Comparison
Semaglutide and tirzepatide are both prescription incretin-based medicines, but they act on different receptor systems and are sold in indication-specific products.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GIP/GLP-1 receptor agonist |
| Regulatory status | FDA-approved active ingredient in specific prescription products | FDA-approved active ingredient in specific prescription products |
| Evidence | Large randomized clinical-trial programs | Large randomized clinical-trial programs |
| Key point | Brand and indication matter | Brand and indication matter |
How to interpret this comparison
A comparison should not be read as a recommendation to use either compound. The more important questions are whether the product is approved for the intended use, whether controlled human evidence exists, and whether safety is understood well enough for clinical decision-making.
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.
Research sources
Use primary and authoritative sources when evaluating claims about this compound. Search results can change as new research is published.